Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

Sponsored:

Wednesday, May 20, 2026

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. licensing rights to ALA-002, PharmAla’s next-generation non-racemic MDMA therapeutic. The proposed agreement carries a potential value exceeding US$100 million through a combination of upfront payments, development milestones, and future royalty revenue. PharmAla will retain all rights to ALA-002 outside of the United States, including its existing Australian operations through Cortexa.

Under the proposed terms, PharmAla would receive US$3.33 million upfront, made up of cash and Jupiter common shares, with additional milestone payments and royalties tied to the product’s future development and commercialization in the U.S. Jupiter has also agreed to deposit US$600,000 into escrow as part of the transaction process, with the definitive agreement expected to close within 90 days.

ALA-002 is a patented MDMA-based Novel Chemical Entity recognized by the FDA and designed to deliver improved cardiovascular safety and reduced abuse potential compared to traditional MDMA formulations. The therapy is currently being supplied into multiple U.S. government-backed clinical trials, including studies involving the VA and Defense Health Agency. PharmAla said the partnership would provide a dedicated U.S. commercialization platform for ALA-002 while allowing the company to continue advancing its broader international MDXX strategy.

Shares of MDMA are currently up 26.67% at $0.19, while its U.S.-listed counterpart, MDXXF, has climbed 30.77% to $0.1394. Meanwhile, shares of JUNS are also surging, rising 36.28% to $0.4361. All figures are as of mid-morning trading.

Sponsored: